AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, leads to greater immune activation and reduced tumor growth when combined with chemotherapy
Titel:
AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, leads to greater immune activation and reduced tumor growth when combined with chemotherapy
Auteur:
Schindler, U. Seitz, L. Ashok, D. Piovesan, D. Tan, J. DiRenzo, D. Yin, F. Leleti, M. Rosen, B. Miles, D. Jin, L. Park, T. Young, S. Soriano, F. Rieger, A. Karakunnel, J. Sharif, E. Powers, J.P. Walters, M.J.